Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
| Parameter | Ipamorelin | Hexarelin | | :--- | :--- | :--- | | **Primary Target Receptor** | GHS-R1a (Ghrelin Receptor) | GHS-R1a & CD36 Scavenger Receptor | | **Selectivity Profile** | Highly Selective (No Cortisol/Prolactin) | Non-Selective (Elevates Cortisol & Prolactin) | | **Relative GH Potency** | Moderate (Pulsatile) | Very High (High Amplitude) | | **Tachyphylaxis Risk** | Low (Sustained response) | High (Rapid receptor desensitization) | | **Cardioprotective Pathways** | Indirect (via GH/IGF-1) | Direct (via CD36) & Indirect (via GH) | | **Primary Experimental Focus** | Selective GH kinetics, bone/muscle assays | Ischemia/reperfusion, acute GH spikes | This breakdown highlights why ipamorelin is favored for baseline metabolic and long-term somatotrophic research, while hexarelin remains a critical tool for acute cardiac ischemia models and high-potency receptor desensitization assays
Peptide safety varies considerably
Glycine-based compounds may actually improve GI tolerability rather than worsening it
Precision theranostics in cervical Cancer: harnessing stimuli-responsive hydrogels for tumor microenvironment-targeted therapy and diagnosis
